Clinical decision-making by gastroenterologists and hepatologists for patients with early hepatocellular carcinoma

Annals of Surgical Oncology

Volumn 21, Issue 6, 2014, Pages 1844-1851

  Nathan, Hari ^a   Herlong, H Franklin ^a   Gurakar, Ahmet ^a   Li, Zhiping ^a   Koteish, Ayman A ^a   Bridges, John F P ^b   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN;

ALCOHOL ABUSE; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER SIZE; CANCER SURGERY; CANCER THERAPY; CLINICAL DECISION MAKING; CONTROLLED STUDY; E-MAIL; EARLY CANCER; GASTROENTEROLOGIST; HEALTH SURVEY; HEPATITIS B; HEPATITIS C; HEPATOLOGIST; HUMAN; HUMAN EXPERIMENT; INTRA ARTERIAL THERAPY; LIKERT SCALE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; PHYSICIAN; RADIOFREQUENCY ABLATION; THROMBOCYTE COUNT; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION; CLINICAL PRACTICE; COMPLICATION; DECISION MAKING; END STAGE LIVER DISEASE; GASTROENTEROLOGY; LIVER NEOPLASMS; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; DECISION MAKING; END STAGE LIVER DISEASE; GASTROENTEROLOGY; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PHYSICIAN'S PRACTICE PATTERNS; PLATELET COUNT; SEVERITY OF ILLNESS INDEX; TUMOR BURDEN;

EID: 84902132495     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3536-6     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
2. Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17(5):1226-33.
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-9.
4. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 1999;19(3):311-22.
5. Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249(5):799-805.
6. Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, et al. Experience of 1,000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer. 2001;91(8):1479-86.
7. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243(3):321-8.
8. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49(2):453-9.
9. Cunningham SC, Tsai S, Marques HP, Mira P, Cameron A, Barroso E, et al. Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Ann Surg Oncol. 2009;16(7):1820-31.
10. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30(6):1434-40.
11. Bellavance EC, Lumpkins KM, Mentha G, Marques HP, Capussotti L, Pulitano C, et al. Surgical management of early-stage hepatocellular carcinoma: resection or transplantation? J Gastrointest Surg. 2008;12(10):1699-708.
12. Nathan H, Bridges JF, Schulick RD, Cameron AM, Hirose K, Edil BH, et al. Understanding surgical decision making in early hepatocellular carcinoma. J Clin Oncol. 2011;29(6):619-25.
13. Nathan H, Segev DL, Bridges JF, Massie AB, Cameron AM, Hirose K, et al. Influence of nonclinical factors on choice of therapy for early hepatocellular carcinoma. Ann Surg Oncol. 2013;20(2):448-56.
14. Luce RD, Tukey JW. Simultaneous conjoint measurement: a new type of fundamental measurement. J Math Psychol. 1964;1(1):1-27.
15. Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and applications. Cambridge, New York: Cambridge University Press; 2000.
16. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000;320(7248):1530-3.
17. Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403-13.
18. Barritt AS IV, Telloni SA, Potter CW, Gerber DA, Hayashi PH. Local access to subspecialty care influences the chance of receiving a liver transplant. Liver Transpl. 2013;19(4):377-82.
19. Davila JA, Kramer JR, Duan Z, Richardson PA, Tyson GL, Sada YH, et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57(5):1858-68.
20. Hedayat A, Sloane NJA, Stufken J. Orthogonal arrays: theory and applications. New York: Springer; 1999.
21. Long JS, Freese J. Regression models for categorical dependent variables using Stata. 2nd ed. College Station: StataCorp LP; 2006.
22. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-2.
23. Kirwan JR, Chaput de Saintonge DM, Joyce CR, Holmes J, Currey HL. Inability of rheumatologists to describe their true policies for assessing rheumatoid arthritis. Ann Rheum Dis. 1986;45(2):156-61.
24. Krupski TL, Kwan L, Afifi AA, Litwin MS. Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol. 2005;23(31):7881-8.
25. El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44(1):158-66.
26. Hawley ST, Hofer TP, Janz NK, Fagerlin A, Schwartz K, Liu L, et al. Correlates of between-surgeon variation in breast cancer treatments. Med Care. 2006;44(7):609-16.
27. Riall TS, Nealon WH, Goodwin JS, Zhang D, Kuo YF, Townsend CM Jr, et al. Pancreatic cancer in the general population: Improvements in survival over the last decade. J Gastrointest Surg. 2006;10(9):1212-23; discussion 1223-1214.
28. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246(2):173-80.
29. Fairfield KM, Lucas FL, Earle CC, Small L, Trimble EL, Warren JL. Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the Medicare population. Cancer. 2010;116(20):4840-8.
30. Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, Tseng JF. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer. 2011;117(5):1019-26.
31. Keating NL, Landrum MB, Lamont EB, Bozeman SR, McNeil BJ. Area-level variations in cancer care and outcomes. Med Care. 2012;50(5):366-73.
32. Nathan H, Hyder O, Mayo SC, Hirose K, Wolfgang CL, Choti MA, et al. Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg. 2013;258(6):1022-7.
33. Wennberg J, Gittelsohn. Small area variations in health care delivery. Science. 1973;182(4117):1102-8.
34. Wennberg J, Gittelsohn A. Variations in medical care among small areas. Sci Am. 1982;246(4):120-34.
35. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med. 2003;138(4):273-87.
36. Riall TS, Lillemoe KD. Underutilization of surgical resection in patients with localized pancreatic cancer. Ann Surg. 2007;246(2):181-2.
37. Teh SH, Nagorney DM, Stevens SR, Offord KP, Therneau TM, Plevak DJ, et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology. 2007;132(4):1261-9.
38. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.
39. Ma YT, Palmer DH. Impact of restricting access to high-cost medications for hepatocellular carcinoma. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):465-73.
40. Rovner DR, Rothert ML, Holmes MM. Validity of structured cases to study clinical decision making. Clin Res. 1986;34(2):A834-A834.
41. Bouma BJ, van der Meulen JH, van den Brink RB, Smidts A, Cheriex EC, Hamer HP, et al. Validity of conjoint analysis to study clinical decision making in elderly patients with aortic stenosis. J Clin Epidemiol. 2004;57(8):815-23.